According to the KDIGO 2024 guidelines, it is strongly recommended to treat patients with T2DM, CKD, and an eGFR ≥20 mL/min per 1.73 m2 with an SGLT2 inhibitor (1A). Here, SLC5A2 is linked to type 2 diabetes mellitus.